ClinicalTrials.gg
Not yet recruitingNCT07947693BILE-PREDICTUpdated Nov 19, 2026

Risk Factors and Early Predictors of Bile Leak After Major Liver Resection

An observational study in Bile Leak, Biliary Fistula and Postoperative Complications, sponsored by Minia University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Minia University · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 44 studies in Postoperative Complications with a site in Egypt — 13 open to participants now, 15 under way, 1 of them phase 3. Postoperative Complications · Egypt.

Planned enrollment
7th of 14
100 · median 85
Started
2026
with 8 others
Observational
14 of 44
6 open now
Primary completion
2028-08
later than 14 of 14 live
Registered
44th of 44
by date
Lead sponsor
6 of 44
Minia University

Among the 44 studies in Postoperative Complications with a site in Egypt, this one is the 7th largest by planned enrollment of the 14 observational ones that give a count, is one of 9 that started in 2026, is one of 14 observational ones, reaches primary completion later than 14 of the 14 other live ones, and was the 44th registered.

Postoperative Complications

1,338 studies on the registry are indexed under Postoperative Complications; 311 are open to participants now.

Browse Postoperative Complications studies →

Open to participants now

13 of the 44 studies in Postoperative Complications with a site in Egypt are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 201 Postoperative Complications studies recruiting now, 126 (63%) set no upper age limit and 32 (16%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Postoperative Complications with a site in Egypt, or all of them as a file.
02

Study summary

The goal of this observational study is to learn how often bile leaks after major liver surgery, which factors increase the risk of a leak, and whether simple bilirubin tests on the fluid collected by the surgical drain in the first days after the operation can predict a serious leak. The study will include adults having planned removal of three or more liver segments (major hepatectomy) for any reason at Minia University, Egypt.

The main questions it aims to answer are:

  • How many patients develop a clinically relevant bile leak (one that needs a drainage procedure, an endoscopic procedure or a second operation) within 90 days after major hepatectomy?
  • Which patient, liver and operation-related factors are linked to bile leak?
  • Can the bilirubin level in the drain fluid, and its ratio to the blood bilirubin level, measured on days 1 and 3 after surgery, show which patients will develop a clinically relevant bile leak?

Participants are adults whose liver operation has already been planned as part of their regular medical care. Taking part does not change their operation or treatment. Participants will:

  • Have their usual pre-operative tests, operative details and hospital course recorded.
  • Have bilirubin measured in a small sample of the fluid collected by the abdominal drain placed at the end of the operation, together with a routine blood test, on days 1, 3 and 5 after surgery and later while the drain remains in place.
  • Be seen daily in hospital and at clinic visits about 2 weeks, 6 weeks and 90 days after surgery.

The researchers expect that higher drain-fluid bilirubin and a higher drain-to-blood bilirubin ratio early after surgery will identify patients at risk of a clinically relevant leak. If so, these simple tests could help surgeons decide when a drain can be removed safely and when a patient needs early investigation.

Read the detailed description

Background

Bile leak is one of the most frequent complications of liver resection and an important cause of morbidity after hepatectomy. In 2011 the International Study Group of Liver Surgery (ISGLS) defined post-hepatectomy bile leak as a bilirubin concentration in the drain fluid at least 3 times the simultaneous serum bilirubin concentration on or after postoperative day (POD) 3, or the need for radiological or operative intervention for biliary collections or bile peritonitis. Severity is graded by its effect on clinical management: grade A causes no change in management, grade B requires active therapeutic intervention without relaparotomy, and grade C requires relaparotomy (Koch et al., 2011).

Prospective ISGLS-graded series show a wide range of incidence. In an international multicenter study of 949 consecutive liver resections, bile leak occurred in 7.3% of patients (grade A 3.3%, grade B 3.4%, grade C 0.6%); severity correlated with the Clavien-Dindo classification, and median hospital stay increased from 7 to 15 days when a leak occurred (Brooke-Smith et al., 2015). In 501 consecutive resections the overall rate was 14.0% (grade B 8.0%, grade C 3.2%), and pre-operative chemotherapy, major hepatectomy and biliodigestive reconstruction were independent risk factors (Spetzler et al., 2019). In 265 elective resections, grade B and grade C leaks occurred in 14.3% and 4.1% of patients, with perioperative mortality of 5.2% and 45.4%, respectively (Rahbari et al., 2012).

Other reported risk factors include central hepatectomy, prolonged operative time and Child-Pugh class B cirrhosis (Nakano et al., 2018), and non-anatomical resection (Panaro et al., 2016; Kajiwara et al., 2016). A 2023 meta-analysis of 39 studies including 43,824 patients identified, among other factors, repeat hepatectomy, extended hepatectomy, diabetes, Child-Pugh class B or worse and chemotherapy as factors associated with grade B/C bile leak (Xue et al., 2023).

Early biochemical detection is attractive because it could allow safe early drain removal in low-risk patients and prompt investigation in those developing a clinically relevant leak. A drain-fluid bilirubin concentration of 2.4 mg/dL or more on POD 2 independently predicted grade B/C leak (odds ratio 11.88, 95% CI 5.33 to 26.49) (Rahbari et al., 2012). After complex hepatectomy, drain-fluid total bilirubin on POD 3 had the highest predictive value for grade B leak (Taguchi et al., 2014), and in 576 resections the drain-to-serum bilirubin ratio discriminated grade B/C leak with areas under the curve of 0.788 on POD 1, 0.791 on POD 2 and 0.650 on POD 3 (Sliwinski et al., 2023).

Rationale

Most published evidence is retrospective, heterogeneous in definitions, case mix and drainage policy, and drawn from mixed minor and major resections. Prospective data that apply the ISGLS definition uniformly to major hepatectomy, and that evaluate pre-operative, intraoperative and early biochemical predictors in the same cohort, remain limited. Drain-fluid bilirubin and the drain-to-serum bilirubin ratio are inexpensive and widely available, and could directly inform drain management and enhanced-recovery pathways. No prospective ISGLS-based analysis of bile leak after major hepatectomy has been reported from this institution.

Objectives

Primary objective: to estimate the incidence of clinically relevant (ISGLS grade B/C) bile leak within 90 days after major hepatectomy.

Secondary objectives:

  • To estimate the incidence of any (grade A/B/C) bile leak.
  • To identify pre-operative and intraoperative factors associated with bile leak by univariable and exploratory multivariable analysis.
  • To evaluate the diagnostic accuracy (area under the curve, sensitivity, specificity and optimal cut-off) of drain-fluid total bilirubin, drain-fluid direct bilirubin and the drain-to-serum bilirubin ratio on POD 1 and POD 3 for predicting clinically relevant bile leak.
  • To describe the management and clinical course of bile leak (interventions required and time to resolution) and its association with post-hepatectomy liver failure, overall morbidity (Clavien-Dindo grade and Comprehensive Complication Index), length of stay and 90-day mortality.

Hypotheses

Null hypothesis: early drain-fluid bilirubin and the drain-to-serum bilirubin ratio do not discriminate between patients who do and do not develop clinically relevant bile leak, and the candidate pre-operative and intraoperative factors are not associated with bile leak.

Alternative hypothesis: higher early drain-fluid bilirubin and a higher drain-to-serum bilirubin ratio are associated with, and predictive of, clinically relevant bile leak, and defined pre-operative and intraoperative factors are independently associated with its occurrence.

Design and Setting

Single-center, prospective, observational cohort study, conducted and reported in accordance with the STROBE statement (von Elm et al., 2007). The study takes place in the Hepato-Pancreato-Biliary (HPB) Unit, Department of General Surgery, Liver and Gastrointestinal Tract Hospital, Faculty of Medicine, Minia University, Minia, Egypt, and forms the thesis research for the Master of Science degree in General Surgery, Faculty of Medicine, Minia University.

Participants and Enrollment

Consecutive adults scheduled for elective major hepatectomy are screened and, after written informed consent, enrolled at the decision to operate (consecutive, total-population sampling). The eligibility criteria are listed in the Eligibility section of this record. Participants in whom no abdominal drain is placed (unless bile leak is diagnosed by intervention), and those who die within 72 hours of surgery from a cause unrelated to bile leak, are recorded as non-evaluable for the primary outcome and reported in the STROBE flow diagram.

Operational Definitions

  • Major hepatectomy: resection of 3 or more contiguous Couinaud segments.
  • Bile leak (ISGLS): drain-fluid bilirubin at least 3 times the simultaneous serum bilirubin on or after POD 3, or the need for radiological or operative intervention for biliary collection or bile peritonitis. Grade A: no change in management; grade B: active therapeutic intervention without relaparotomy; grade C: relaparotomy.
  • Clinically relevant bile leak: ISGLS grade B or C (primary outcome).
  • Post-hepatectomy liver failure (ISGLS): increased international normalized ratio (INR) with concomitant hyperbilirubinemia on or after POD 5, graded A to C (Rahbari et al., Surgery 2011).
  • Post-hepatectomy hemorrhage (ISGLS): defined and graded according to the ISGLS (Rahbari et al., HPB 2011).
  • Overall morbidity: graded by the Clavien-Dindo classification (Dindo et al., 2004) and summarized by the Comprehensive Complication Index (Slankamenac et al., 2013).
  • Drain-to-serum bilirubin ratio: drain-fluid total bilirubin divided by the simultaneous serum total bilirubin, calculated on POD 1 and POD 3.

Study Procedures

Pre-operative assessment: history and examination, routine hematology and biochemistry (including liver profile, INR and albumin), tumor markers as indicated, and triphasic computed tomography and/or magnetic resonance imaging with volumetric assessment of the future liver remnant when major resection is planned. Liver function is characterized by Child-Pugh class and, where available, indocyanine green retention at 15 minutes (ICG-R15). Baseline variables are recorded prospectively on the case report form.

Operation and drainage: resections are performed by the unit's HPB surgeons according to standard practice (open or minimally invasive), with parenchymal transection and hemostasis by the operator's usual technique. The biliary integrity of the cut surface is assessed according to unit practice, and use of an intraoperative bile-leak test is recorded. In line with the unit's drainage practice after major hepatectomy, a closed-suction abdominal drain is placed adjacent to the transection surface at the end of the procedure, including all cases with biliary reconstruction; the protocol standardizes drain position and the sampling schedule so that bile leak can be assessed uniformly. Operative details are recorded at the time of surgery.

Postoperative sampling and monitoring:

  • Drain-fluid total and direct bilirubin on POD 1 and POD 3, and on POD 5 and subsequently while the drain remains in place, each with a simultaneous serum total bilirubin to calculate the drain-to-serum ratio.
  • Daily drain output volume and character.
  • Serum liver profile, INR, C-reactive protein and white cell count at least on POD 1, 3 and 5, per unit protocol.
  • Drain removal, escalation of care and any radiological, endoscopic or surgical intervention, each with its indication.

Samples are analyzed in the hospital laboratory and are not stored. Drain removal and all management decisions remain with the treating team; no experimental intervention is imposed.

Outcome ascertainment and follow-up: participants are assessed daily during the index admission and reviewed in the outpatient clinic approximately 2 weeks, 6 weeks and 90 days after surgery, or more often if clinically indicated. Readmissions and interventions within 90 days are captured. Bile leak, post-hepatectomy liver failure and post-hepatectomy hemorrhage are graded according to the ISGLS definitions; the diagnosis and grade of bile leak are assigned prospectively by the managing team and independently verified by the investigators.

Candidate Predictors

  • Demographic and baseline: age, sex, body mass index, smoking, diabetes mellitus, American Society of Anesthesiologists (ASA) physical status, and nutritional risk (serum albumin, weight loss).
  • Hepatic and disease-related: underlying diagnosis; cirrhosis and Child-Pugh class; portal hypertension; pre-operative jaundice (obstructive or non-obstructive); ICG-R15 where available; serum bilirubin, albumin, INR, platelet count, transaminases and alkaline phosphatase; future liver remnant volume where measured.
  • Neoadjuvant and pre-operative: systemic chemotherapy; biliary drainage or intervention (endoscopic or percutaneous).
  • Operative: extent of resection (right, left, extended or central); anatomical or non-anatomical resection; biliary reconstruction (hepaticojejunostomy); hilar dissection or caudate involvement; operative time; estimated blood loss; intraoperative transfusion; Pringle maneuver and total clamp time; cut-surface area; intraoperative bile-leak test; concomitant procedures.
  • Early postoperative: drain-fluid total and direct bilirubin and the drain-to-serum total bilirubin ratio on POD 1 and POD 3; daily drain output volume; serum bilirubin trajectory; C-reactive protein and white cell count on POD 3.

Sample Size

The sample size is based on the primary descriptive objective, estimating a single proportion with adequate precision. The expected incidence of clinically relevant bile leak after major hepatectomy is 12%; in prospective ISGLS-graded series of all liver resections, grade B/C leak occurred in 4.0% to 18.4% of patients, and major hepatectomy was an independent risk factor (Brooke-Smith et al., 2015; Spetzler et al., 2019; Rahbari et al., 2012). With 95% confidence (Z = 1.96) and an absolute precision of plus or minus 8%, n = Z² × p(1 - p) / d² = (1.96² × 0.12 × 0.88) / 0.08² = 63.4, rounded up to 64 evaluable patients. Allowing about 10% non-evaluable patients (early unrelated death, absent drain or loss to follow-up), at least 72 patients are required.

To strengthen the risk-factor and diagnostic-accuracy objectives, all consecutive eligible patients presenting during the 18-month recruitment period will be enrolled, with a target of at least 90 evaluable patients (about 100 enrolled). With 90 evaluable patients, the 95% confidence interval for an incidence of 12% has a half-width of about plus or minus 6.7%. At the anticipated incidence, 90 patients yield roughly 10 to 12 grade B/C events, a low number of events per variable (Peduzzi et al., 1996); multivariable modeling is therefore pre-specified as exploratory. Where feasibility permits, recruitment may be extended to accrue additional events, and this record will be updated accordingly.

Statistical Analysis

Analyses will use SPSS or R, with two-sided tests and a significance level of 0.05.

  • Descriptive statistics: continuous variables as mean (SD) or median (IQR) according to distribution (Shapiro-Wilk test); categorical variables as frequencies and percentages. The incidence of bile leak, overall and by grade, is reported with 95% confidence intervals.
  • Univariable comparisons: patients with and without bile leak are compared with the independent-samples t test or Mann-Whitney U test for continuous variables, and the chi-square or Fisher exact test for categorical variables.
  • Exploratory multivariable analysis: variables with P \< 0.10 on univariable analysis, together with clinically important predictors, are entered into a Firth penalized-likelihood logistic regression model, with the number of covariates limited by the number of events. Adjusted odds ratios with 95% confidence intervals are reported; discrimination is assessed by the area under the curve and calibration by the Hosmer-Lemeshow test.
  • Diagnostic accuracy of early predictors: receiver operating characteristic (ROC) analysis quantifies the area under the curve (AUC) of drain-fluid total bilirubin, drain-fluid direct bilirubin and the drain-to-serum bilirubin ratio on POD 1 and POD 3 for clinically relevant (grade B/C) bile leak. Optimal cut-offs are identified by the Youden index and reported with sensitivity, specificity and predictive values; AUCs on POD 1 and POD 3 are compared by the DeLong method.
  • Because grade B/C events are expected to be few, the AUCs of the POD 1 parameters are also evaluated against bile leak of any grade. POD 3 values are not evaluated against any-grade leak, because the ISGLS biochemical criterion is applied from POD 3 and its use would bias the estimates (incorporation bias).
  • Missing data: the extent and pattern of missing data are reported; complete-case analysis is used with a sensitivity analysis, and multiple imputation is considered if data are plausibly missing at random.
  • Pre-specified subgroup descriptions, by extent of resection and by biliary reconstruction, are reported where numbers permit.

Data Management and Quality Control

Data are recorded prospectively on a standardized case report form, pseudonymized with a study identification number, and entered into a secured, access-controlled electronic database with range and consistency checks at entry. The case report form is piloted and finalized before enrollment begins. Source documents are retained according to institutional policy to permit verification, and only the investigators have access to the data.

Ethical Considerations

The protocol was approved by the Medical Research Ethics Committee (Institutional Review Board), Faculty of Medicine, Minia University (MUFMIRB approval number 2259:11/26, 4 November 2026), which operates according to the Declaration of Helsinki, CIOMS and ICH-GCP guidelines and Egyptian Law No. 214 of 2020. The study is conducted in accordance with the Declaration of Helsinki (2013 revision). Written informed consent is obtained from every participant; participation is voluntary, and refusal does not affect the standard of care. The study observes routine surgical care: the standardized drain position and drain-fluid sampling add minimal incremental risk, and treatment decisions remain with the treating team. Serious adverse events are reported immediately to the committee chair, protocol changes are implemented only after committee approval, an annual report is submitted (the approval is valid for one year and will be renewed), and an end-of-study notification is filed.

Timeline

Ethical approval was granted on 4 November 2026, and the study is registered before enrollment begins. Prospective enrollment runs for 18 months, from 25 November 2026 to 24 May 2028; 90-day follow-up is completed by August 2028, followed by analysis and thesis write-up and submission by October 2028.

Reporting and Dissemination

Results will be reported according to the STROBE statement, presented as an MSc thesis and submitted for publication in a peer-reviewed journal.

Limitations

The single-center design may limit generalizability; the expected number of events constrains multivariable modeling, which is exploratory and hypothesis-generating; routine drainage differs from selective or no-drain policies; and case mix (indication, extent of resection and biliary reconstruction) is heterogeneous.

03

Conditions studied

  • Bile Leak
  • Biliary Fistula
  • Postoperative Complications
  • Hepatectomy
  • Liver Neoplasms

Keywords

  • Major hepatectomy
  • Liver resection
  • Bile leakage
  • Post-hepatectomy bile leak
  • ISGLS
  • Drain fluid bilirubin
  • Drain-to-serum bilirubin ratio
  • Early predictor
  • Risk factors
  • Diagnostic accuracy
  • Hepatocellular carcinoma
  • Colorectal liver metastases
  • Cholangiocarcinoma
  • Post-hepatectomy liver failure
  • Clavien-Dindo classification
  • Comprehensive Complication Index
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive adults scheduled for elective major hepatectomy (resection of 3 or more contiguous Couinaud segments) for malignant or benign liver disease at the Hepato-Pancreato-Biliary Unit, Liver and Gastrointestinal Tract Hospital, Faculty of Medicine, Minia University, Minia, Egypt, during an 18-month recruitment period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Scheduled for elective major hepatectomy, defined as resection of three or more contiguous Couinaud segments (for example right or left hepatectomy, right or left trisectionectomy, or extended or central major resection), by an open or minimally invasive approach.
  • Any underlying indication, including hepatocellular carcinoma, colorectal or non-colorectal liver , cholangiocarcinoma, other primary liver tumors, or benign disease.
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Minor resection (fewer than three contiguous segments) or non-anatomical wedge resection only.
  • Emergency hepatectomy (for example for trauma or spontaneous tumor rupture).
  • Liver transplantation or living-donor hepatectomy.
  • Two-stage hepatectomy or associating liver partition and portal vein ligation for staged hepatectomy (ALPPS).
  • Simultaneous major resection of another organ that itself involves a biliary or enteric anastomosis confounding drain-fluid biochemistry (for example pancreatoduodenectomy).
  • No intraoperative abdominal drain placed, unless bile leak is diagnosed by radiological or operative intervention (assessed at surgery; participant recorded as non-evaluable).
  • Death within 72 hours of surgery from a cause unrelated to bile leak (participant recorded as non-evaluable).
  • Refusal of consent or inability to complete 90-day follow-up.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Major hepatectomy cohort

    Consecutive adults (18 years or older) undergoing elective major hepatectomy (resection of 3 or more contiguous Couinaud segments) for any malignant or benign indication at the HPB Unit, Liver and Gastrointestinal Tract Hospital, Minia University. All participants receive standard peri-operative care. A closed-suction drain is placed adjacent to the transection surface at the end of surgery according to unit practice, and drain-fluid total and direct bilirubin, with simultaneous serum bilirubin, are measured on postoperative days 1, 3 and 5 and thereafter while the drain remains. Participants are followed for 90 days. The investigators do not assign or modify treatment.

    Procedure: Major hepatectomy · Diagnostic Test: Drain-fluid and serum bilirubin measurement

Interventions

  • ProcedureMajor hepatectomy

    Elective resection of 3 or more contiguous Couinaud segments (right or left hepatectomy, right or left trisectionectomy, or extended or central major resection), open or minimally invasive, with or without biliary reconstruction, performed by the unit's HPB surgeons according to standard practice and ending with placement of a closed-suction drain adjacent to the transection surface. The operation is clinically indicated and planned before enrollment; the study does not assign or modify it.

    Also known as: Major liver resection, Hemihepatectomy, Trisectionectomy

  • Diagnostic testDrain-fluid and serum bilirubin measurement

    Total and direct (conjugated) bilirubin measured in fluid from the closed-suction abdominal drain on postoperative days 1 and 3, and on day 5 and subsequently while the drain remains, each with a simultaneous serum total bilirubin to calculate the drain-to-serum bilirubin ratio. Fluid is taken from the drain collection without any additional procedure, analyzed in the hospital laboratory and not stored. Drain management remains at the discretion of the treating team.

    Also known as: Drain bilirubin, Drain-to-serum bilirubin ratio, Bilirubin ratio

06

What researchers measure

Primary outcomes

  1. Incidence of Clinically Relevant (ISGLS Grade B or C) Bile Leak

    Number and percentage of participants who develop bile leak of International Study Group of Liver Surgery (ISGLS) grade B or C, reported with a 95% confidence interval. Bile leak is defined as a drain-fluid bilirubin concentration at least 3 times the simultaneous serum bilirubin concentration on or after postoperative day 3, or the need for radiological or operative intervention for biliary collection or bile peritonitis. Grade B requires active therapeutic intervention (for example percutaneous drainage or endoscopic retrograde cholangiopancreatography with or without stenting) without relaparotomy; grade C requires relaparotomy. Diagnosis and grade are assigned prospectively by the treating team and independently verified by the investigators against the ISGLS criteria.

    Time frame: From surgery to 90 days after surgery

Secondary outcomes

  1. Incidence of Any ISGLS Bile Leak (Grade A, B or C)

    Number and percentage of participants who meet the ISGLS definition of bile leak of any grade, reported with a 95% confidence interval. Grade A causes no change in clinical management; grades B and C are defined as for the primary outcome.

    Time frame: From surgery to 90 days after surgery

  2. Severity Grade of Bile Leak (ISGLS Grade A, B and C)

    Number and percentage of participants with ISGLS grade A, grade B and grade C bile leak, respectively, reported among all evaluable participants and among those with bile leak.

    Time frame: From surgery to 90 days after surgery

  3. Time From Surgery to Diagnosis of Bile Leak

    Postoperative day on which bile leak is first diagnosed according to the ISGLS definition (first drain-to-serum bilirubin ratio of 3 or more on or after postoperative day 3, or date of the first intervention for biliary collection or bile peritonitis), reported as median and interquartile range among participants with bile leak.

    Time frame: From surgery to 90 days after surgery

  4. Pre-operative and Intraoperative Factors Associated With Bile Leak

    Odds ratios with 95% confidence intervals for the association of each pre-specified candidate factor with bile leak of any grade and with clinically relevant (grade B/C) bile leak, from univariable analysis and an exploratory Firth penalized multivariable logistic regression model in which the number of covariates is limited by the number of events. Candidate factors: demographic and baseline (age, sex, body mass index, smoking, diabetes, ASA class, albumin, weight loss); hepatic and disease-related (diagnosis, cirrhosis and Child-Pugh class, portal hypertension, pre-operative jaundice, ICG-R15, liver tests, platelet count, future liver remnant volume); pre-operative chemotherapy and biliary drainage; operative (extent and type of resection, biliary reconstruction, hilar dissection or caudate involvement, operative time, blood loss, transfusion, Pringle maneuver and clamp time, cut-surface area, bile-leak test, concomitant procedures).

    Time frame: Pre-operative and intraoperative data; bile leak assessed from surgery to 90 days after surgery

  5. Accuracy of Drain-Fluid Total Bilirubin on Postoperative Days 1 and 3 for Predicting Clinically Relevant Bile Leak

    Area under the receiver operating characteristic curve (AUC) with 95% confidence interval of the drain-fluid total bilirubin concentration (mg/dL) measured on postoperative day 1 and on postoperative day 3 for predicting ISGLS grade B or C bile leak. For each day, the optimal cut-off (maximum Youden index) is reported with its sensitivity, specificity and positive and negative predictive values. The AUCs on days 1 and 3 are compared by the DeLong method.

    Time frame: Measured on postoperative days 1 and 3; bile leak assessed to 90 days after surgery

  6. Accuracy of Drain-Fluid Direct Bilirubin on Postoperative Days 1 and 3 for Predicting Clinically Relevant Bile Leak

    Area under the receiver operating characteristic curve (AUC) with 95% confidence interval of the drain-fluid direct (conjugated) bilirubin concentration (mg/dL) measured on postoperative day 1 and on postoperative day 3 for predicting ISGLS grade B or C bile leak. For each day, the optimal cut-off (maximum Youden index) is reported with its sensitivity, specificity and positive and negative predictive values. The AUCs on days 1 and 3 are compared by the DeLong method.

    Time frame: Measured on postoperative days 1 and 3; bile leak assessed to 90 days after surgery

  7. Accuracy of the Drain-to-Serum Bilirubin Ratio on Postoperative Days 1 and 3 for Predicting Clinically Relevant Bile Leak

    Area under the receiver operating characteristic curve (AUC) with 95% confidence interval of the drain-to-serum total bilirubin ratio (drain-fluid total bilirubin divided by simultaneous serum total bilirubin) measured on postoperative day 1 and on postoperative day 3 for predicting ISGLS grade B or C bile leak. For each day, the optimal cut-off (maximum Youden index) is reported with its sensitivity, specificity and positive and negative predictive values. The AUCs on days 1 and 3 are compared by the DeLong method.

    Time frame: Measured on postoperative days 1 and 3; bile leak assessed to 90 days after surgery

  8. Accuracy of Postoperative Day 1 Drain-Fluid Total Bilirubin for Predicting Bile Leak of Any Grade

    AUC with 95% confidence interval of the drain-fluid total bilirubin concentration (mg/dL) on postoperative day 1 for predicting ISGLS bile leak of any grade (A, B or C), with the optimal cut-off (maximum Youden index) and its sensitivity, specificity and positive and negative predictive values. Day 3 values are not evaluated against any-grade leak because the ISGLS biochemical criterion is applied from postoperative day 3 (incorporation bias).

    Time frame: Measured on postoperative day 1; bile leak assessed to 90 days after surgery

  9. Accuracy of Postoperative Day 1 Drain-Fluid Direct Bilirubin for Predicting Bile Leak of Any Grade

    AUC with 95% confidence interval of the drain-fluid direct (conjugated) bilirubin concentration (mg/dL) on postoperative day 1 for predicting ISGLS bile leak of any grade (A, B or C), with the optimal cut-off (maximum Youden index) and its sensitivity, specificity and positive and negative predictive values. Day 3 values are not evaluated against any-grade leak because the ISGLS biochemical criterion is applied from postoperative day 3 (incorporation bias).

    Time frame: Measured on postoperative day 1; bile leak assessed to 90 days after surgery

  10. Accuracy of the Postoperative Day 1 Drain-to-Serum Bilirubin Ratio for Predicting Bile Leak of Any Grade

    AUC with 95% confidence interval of the drain-to-serum total bilirubin ratio on postoperative day 1 for predicting ISGLS bile leak of any grade (A, B or C), with the optimal cut-off (maximum Youden index) and its sensitivity, specificity and positive and negative predictive values. Day 3 values are not evaluated against any-grade leak because the ISGLS biochemical criterion is applied from postoperative day 3 (incorporation bias).

    Time frame: Measured on postoperative day 1; bile leak assessed to 90 days after surgery

  11. Discrimination and Calibration of the Exploratory Multivariable Model for Bile Leak

    Apparent discrimination (AUC with 95% confidence interval) and calibration (Hosmer-Lemeshow goodness-of-fit test) of the exploratory Firth penalized logistic regression model of pre-operative and intraoperative factors for bile leak.

    Time frame: Bile leak assessed from surgery to 90 days after surgery

  12. Management of Bile Leak

    Number and percentage of participants with bile leak managed by each of the following (more than one may apply): observation with the drain kept in place; new or prolonged percutaneous drainage; endoscopic retrograde cholangiopancreatography with or without stenting; antibiotic therapy; and relaparotomy.

    Time frame: From diagnosis of bile leak to 90 days after surgery

  13. Time to Resolution of Bile Leak

    Days from diagnosis of bile leak to resolution, defined as cessation of bilious drainage with removal of all abdominal drains and no further biliary intervention, as documented by the treating team; reported as median and interquartile range.

    Time frame: From diagnosis of bile leak to 90 days after surgery

  14. Incidence and Grade of Post-hepatectomy Liver Failure (ISGLS)

    Number and percentage of participants with post-hepatectomy liver failure, defined by the ISGLS as an increased international normalized ratio with concomitant hyperbilirubinemia (local laboratory limits) on or after postoperative day 5, and graded A (no change in clinical management), B (deviation from the regular course without invasive treatment) or C (invasive treatment required); compared between participants with and without bile leak.

    Time frame: From postoperative day 5 to 90 days after surgery

  15. Incidence and Grade of Post-hepatectomy Hemorrhage (ISGLS)

    Number and percentage of participants with post-hepatectomy hemorrhage, defined by the ISGLS as a fall in hemoglobin of more than 3 g/dL from the postoperative baseline, and/or postoperative red cell transfusion for falling hemoglobin, and/or radiological intervention or relaparotomy to stop bleeding; graded A (transfusion of up to 2 units), B (more than 2 units) or C (invasive reintervention).

    Time frame: From surgery to 90 days after surgery

  16. Overall Postoperative Morbidity by Clavien-Dindo Grade

    Number and percentage of participants with any complication and with major complications (grade III or higher), classified by the highest Clavien-Dindo grade (I to V); compared between participants with and without bile leak.

    Time frame: From surgery to 90 days after surgery

  17. Comprehensive Complication Index (CCI)

    Comprehensive Complication Index score (scale 0 to 100; 0 = no complication, 100 = death), calculated from all complications graded by the Clavien-Dindo classification; reported as median and interquartile range and compared between participants with and without bile leak.

    Time frame: From surgery to 90 days after surgery

  18. Reintervention

    Number and percentage of participants requiring radiological, endoscopic or surgical reintervention for any cause, reported overall and by type.

    Time frame: From surgery to 90 days after surgery

  19. Length of Postoperative Hospital Stay

    Days from surgery to discharge from the index admission; reported as median and interquartile range and compared between participants with and without bile leak.

    Time frame: From surgery to discharge from the index admission (up to 90 days)

  20. Length of Intensive Care Unit Stay

    Number of days spent in the intensive care unit during the index admission; reported as median and interquartile range and compared between participants with and without bile leak.

    Time frame: From surgery to discharge from the index admission (up to 90 days)

  21. Hospital Readmission

    Number and percentage of participants readmitted to hospital for any cause, and for bile leak-related causes, after discharge from the index admission.

    Time frame: From discharge to 90 days after surgery

  22. All-Cause Mortality

    Number and percentage of participants who die from any cause within 30 days and within 90 days after surgery; compared between participants with and without bile leak.

    Time frame: 30 days and 90 days after surgery

Other outcomes

  1. Duration of Abdominal Drainage

    Days from surgery to removal of the last abdominal drain; reported as median and interquartile range and compared between participants with and without bile leak.

    Time frame: From surgery to removal of the last drain (up to 90 days)

  2. Incidence of Bile Leak by Type of Resection and Biliary Reconstruction

    Number and percentage of participants with bile leak of any grade and with clinically relevant (grade B or C) bile leak, by extent of resection (right, left, extended or central) and by presence or absence of biliary reconstruction; descriptive only.

    Time frame: From surgery to 90 days after surgery

  3. Early Postoperative Variables Associated With Clinically Relevant Bile Leak

    Comparison of daily drain output volume (postoperative days 1 to 3), serum bilirubin trajectory (postoperative days 1, 3 and 5), and C-reactive protein and white cell count on postoperative day 3 between participants with and without clinically relevant bile leak, reported as median (IQR) or mean (SD) with univariable P values.

    Time frame: Postoperative days 1 to 5; bile leak assessed to 90 days after surgery

07

Study locations

1 site
08

References and documents

Publications

  • Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L, Fan ST, Yokoyama Y, Crawford M, Makuuchi M, Christophi C, Banting S, Brooke-Smith M, Usatoff V, Nagino M, Maddern G, Hugh TJ, Vauthey JN, Greig P, Rees M, Nimura Y, Figueras J, DeMatteo RP, Buchler MW, Weitz J. Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery. 2011 May;149(5):680-8. doi: 10.1016/j.surg.2010.12.002. Epub 2011 Feb 12. PubMed 21316725 ↗
  • Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, Koch M, Makuuchi M, Dematteo RP, Christophi C, Banting S, Usatoff V, Nagino M, Maddern G, Hugh TJ, Vauthey JN, Greig P, Rees M, Yokoyama Y, Fan ST, Nimura Y, Figueras J, Capussotti L, Buchler MW, Weitz J. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011 May;149(5):713-24. doi: 10.1016/j.surg.2010.10.001. Epub 2011 Jan 14. PubMed 21236455 ↗
  • Rahbari NN, Garden OJ, Padbury R, Maddern G, Koch M, Hugh TJ, Fan ST, Nimura Y, Figueras J, Vauthey JN, Rees M, Adam R, Dematteo RP, Greig P, Usatoff V, Banting S, Nagino M, Capussotti L, Yokoyama Y, Brooke-Smith M, Crawford M, Christophi C, Makuuchi M, Buchler MW, Weitz J. Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). HPB (Oxford). 2011 Aug;13(8):528-35. doi: 10.1111/j.1477-2574.2011.00319.x. Epub 2011 Jun 7. PubMed 21762295 ↗
  • Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. doi: 10.1097/01.sla.0000133083.54934.ae. PubMed 15273542 ↗
  • Slankamenac K, Graf R, Barkun J, Puhan MA, Clavien PA. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg. 2013 Jul;258(1):1-7. doi: 10.1097/SLA.0b013e318296c732. PubMed 23728278 ↗
  • Brooke-Smith M, Figueras J, Ullah S, Rees M, Vauthey JN, Hugh TJ, Garden OJ, Fan ST, Crawford M, Makuuchi M, Yokoyama Y, Buchler M, Weitz J, Padbury R. Prospective evaluation of the International Study Group for Liver Surgery definition of bile leak after a liver resection and the role of routine operative drainage: an international multicentre study. HPB (Oxford). 2015 Jan;17(1):46-51. doi: 10.1111/hpb.12322. Epub 2014 Jul 24. PubMed 25059275 ↗
  • Rahbari NN, Elbers H, Koch M, Kirchberg J, Dutlu M, Mehrabi A, Buchler MW, Weitz J. Bilirubin level in the drainage fluid is an early and independent predictor of clinically relevant bile leakage after hepatic resection. Surgery. 2012 Nov;152(5):821-31. doi: 10.1016/j.surg.2012.03.012. Epub 2012 May 30. PubMed 22657729 ↗
  • Xue S, Wang H, Chen X, Zeng Y. Risk factors of postoperative bile leakage after liver resection: A systematic review and meta-analysis. Cancer Med. 2023 Jul;12(14):14922-14936. doi: 10.1002/cam4.6128. Epub 2023 Jun 16. PubMed 37326370 ↗
  • Nakano R, Ohira M, Kobayashi T, Imaoka Y, Mashima H, Yamaguchi M, Honmyo N, Okimoto S, Hamaoka M, Shimizu S, Kuroda S, Tahara H, Ide K, Ohdan H. Independent risk factors that predict bile leakage after hepatectomy for hepatocellular carcinoma: Cohort study. Int J Surg. 2018 Sep;57:1-7. doi: 10.1016/j.ijsu.2018.07.005. Epub 2018 Jul 20. PubMed 30036692 ↗
  • Panaro F, Hacina L, Bouyabrine H, Al-Hashmi AW, Herrero A, Navarro F. Risk factors for postoperative bile leakage: a retrospective single-center analysis of 411 hepatectomies. Hepatobiliary Pancreat Dis Int. 2016 Feb;15(1):81-6. doi: 10.1016/s1499-3872(15)60424-6. PubMed 26818547 ↗
  • Kajiwara T, Midorikawa Y, Yamazaki S, Higaki T, Nakayama H, Moriguchi M, Tsuji S, Takayama T. Clinical score to predict the risk of bile leakage after liver resection. BMC Surg. 2016 May 6;16(1):30. doi: 10.1186/s12893-016-0147-0. PubMed 27154038 ↗
  • Taguchi Y, Ebata T, Yokoyama Y, Igami T, Sugawara G, Kokuryo T, Wakai K, Nagino M. The determination of bile leakage in complex hepatectomy based on the guidelines of the International Study Group of Liver Surgery. World J Surg. 2014 Jan;38(1):168-76. doi: 10.1007/s00268-013-2252-x. PubMed 24146194 ↗
  • Spetzler VN, Schepers M, Pinnschmidt HO, Fischer L, Nashan B, Li J. The incidence and severity of post-hepatectomy bile leaks is affected by surgical indications, preoperative chemotherapy, and surgical procedures. Hepatobiliary Surg Nutr. 2019 Apr;8(2):101-110. doi: 10.21037/hbsn.2019.02.06. PubMed 31098357 ↗
  • Sliwinski S, Heil J, Franz J, El Youzouri H, Heise M, Bechstein WO, Schnitzbauer AA. A critical appraisal of the ISGLS definition of biliary leakage after liver resection. Langenbecks Arch Surg. 2023 Feb 3;408(1):77. doi: 10.1007/s00423-022-02746-8. PubMed 36735087 ↗
  • von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007 Oct 20;370(9596):1453-7. doi: 10.1016/S0140-6736(07)61602-X. PubMed 18064739 ↗
  • Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996 Dec;49(12):1373-9. doi: 10.1016/s0895-4356(96)00236-3. PubMed 8970487 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2028, 21 months later.

Of 277 non-industry observational studies under Postoperative Complications, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 21 months is close to that.

Counting every sponsor, half of 282 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 19, 2026
StartEst.
Nov 25, 2026
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947693
Lead sponsor
Minia University
Responsible party
Saleh Khairy Saleh MD (Lecturer of General Surgery, Department of General Surgery, Minia University) — Principal investigator
First posted
Nov 19, 2026
Start date
Nov 25, 2026 (estimated)
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Saleh Khairy Saleh, MD
Contact
salehkhairy@mu.edu.eg
+20 120 176 5401
Saleh Khairy Saleh, MD
principal investigator · Minia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion